Market News AIOpen the app

Eocene and Barcode Nanotech are making progress on a new Aramchol formula to better target liver and gut tumors.

TrialRead the original at prnewswire.com
Good for EOCN

The new formulation is progress toward directing Aramchol to tumors, which could help Eocene's drug program. The report gives no patient results or proof of benefit, so this remains an early research step.

EOCN · Eocene Ltd.

AI read · Good for EOCN

The AI's read

This gives Eocene a possible new way to direct Aramchol toward tumors. The report says the work may support the drug's effects, but it gives no patient results or proof of benefit. That makes this a favorable research step, not a proven treatment advance.

Get alerts for EOCN

Follow Eocene Ltd. (EOCN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for EOCN
Free on the App Store and Google Play, or on the web.